Ãfrica Flores

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7525563/publications.pdf

Version: 2024-02-01

20 papers	691 citations	623574 14 h-index	752573 20 g-index
21 all docs	21 docs citations	21 times ranked	927 citing authors

#	Article	IF	Citations
1	Long-term rehabilitation reduces task error variability in cervical spinal cord contused rats. Experimental Neurology, 2022, 348, 113928.	2.0	2
2	Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomedicine and Pharmacotherapy, 2022, 149, 112925.	2.5	11
3	Cervical Electrical Neuromodulation Effectively Enhances Hand Motor Output in Healthy Subjects by Engaging a Use-Dependent Intervention. Journal of Clinical Medicine, 2021, 10, 195.	1.0	16
4	Transcutaneous Electrical Neuromodulation of the Cervical Spinal Cord Depends Both on the Stimulation Intensity and the Degree of Voluntary Activity for Training. A Pilot Study. Journal of Clinical Medicine, 2021, 10, 3278.	1.0	14
5	When Spinal Neuromodulation Meets Sensorimotor Rehabilitation: Lessons Learned From Animal Models to Regain Manual Dexterity After a Spinal Cord Injury. Frontiers in Rehabilitation Sciences, 2021, 2, .	0.5	4
6	THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice. Psychopharmacology, 2020, 237, 801-809.	1.5	9
7	The Hypocretin/Orexin System and Fear Learning. , 2019, , 155-170.		0
8	Lost in translation: how to upgrade fear memory research. Molecular Psychiatry, 2018, 23, 2122-2132.	4.1	41
9	When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology, 2018, 157, 43-50.	2.0	20
10	Facilitation of Contextual Fear Extinction by Orexin-1 Receptor Antagonism Is Associated with the Activation of Specific Amygdala Cell Subpopulations. International Journal of Neuropsychopharmacology, 2017, 20, 654-659.	1.0	34
11	CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. Biological Psychiatry, 2017, 81, 625-634.	0.7	24
12	Involvement of the orexin/hypocretin system in the pharmacological effects induced by Î”⁹â€tetrahydrocannabinol. British Journal of Pharmacology, 2016, 173, 1381-1392.	2.7	18
13	Role of Î²4* Nicotinic Acetylcholine Receptors in the Habenuloâ€“Interpeduncular Pathway in Nicotine Reinforcement in Mice. Neuropsychopharmacology, 2016, 41, 1790-1802.	2.8	30
14	Orexins and fear: implications for the treatment of anxiety disorders. Trends in Neurosciences, 2015, 38, 550-559.	4.2	83
15	The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward. Biological Psychiatry, 2014, 75, 499-507.	0.7	38
16	The Hypocretin/Orexin System Mediates the Extinction of Fear Memories. Neuropsychopharmacology, 2014, 39, 2732-2741.	2.8	112
17	A Role for Hypocretin/Orexin Receptor-1 in Cue-Induced Reinstatement of Nicotine-Seeking Behavior. Neuropsychopharmacology, 2013, 38, 1724-1736.	2.8	62
18	Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Frontiers in Neuroscience, 2013, 7, 256.	1.4	55

#	ARTICLE	IF	CITATIONS
19	Hypocretin/Orexin Signaling in the Hypothalamic Paraventricular Nucleus is Essential for the Expression of Nicotine Withdrawal. Biological Psychiatry, 2012, 71, 214-223.	0.7	77
20	Influence of Î´-Opioid Receptors in the Behavioral Effects of Nicotine. Neuropsychopharmacology, 2012, 37, 2332-2344.	2.8	38